Document Detail


Comparison of various methods for assessing infarct-size in the dog.
MedLine Citation:
PMID:  6896819     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Various methods used for the assessment of infarct-size were compared in a canine model of coronary artery occlusion. The ability of molsidomine (an antianginal agent) to reduce infarct-size was also investigated. Open-chest dogs underwent occlusion of the left anterior descending coronary artery and starting 30 min after the occlusion received either molsidomine (n=8) as an infusion at the rate of 1 microgram/kg/min for 30 min and at a rate of 0.75 microgram/kg/min for 2 h, or saline (controls, n=8). Three hours after the occlusion methylene blue was injected into the left atrium for the assessment of the area at risk in vivo (ARV). The animals were then sacrificed, the heart removed and coronary arteriograms made after injection into the left coronary ostium of a BaSO4-gelatin mass to delineate the post-mortem area at risk (ARPM). The hearts were then cut in sections and the infarct's (I) area visualized with nitroblue tetrazolium C1. The left ventricle (LV) and I were also weighed, ARV, ARPM as well as LV and I areas were determined by planimetry. Body weight and LV mass were similar in both groups, I mass however, was markedly lower in molsidomine than in control dogs. Percentages I/LV mass and area were also significantly lower in the treated than in the control animals, and there was a significant correlation between the mass and planimetric methods for determining I size. ARPM/LV % was similar in both groups and I/ARPM % was smaller in molsidomine than in control animals, however this difference was not statistically significant. Molsidomine markedly reduced ARV/LV % which resulted in similar I/ARV ratios both in the treated and control groups. It is concluded: (1) that the direct measurement of I (mass) or the percentages I/LV mass or area are similarly useful for the detection of a pharmacological effect of I size. ARPM is unaffected by drug treatment and thus provides a valid reference point for the assessment of I. ARV may be altered by a pharmacological intervention and thus may give false negative results when used as the basis for expressing I size. (2) Molsidomine is a potent agent for reducing I size.
Authors:
P A Martorana; H Göbel; B Kettenbach; R E Nitz
Related Documents :
15132319 - Assessment of parallel conductance for the trans-cardiac conductance method: can we use...
9049119 - Postnatal changes in left ventricular volume and contractility in healthy term infants.
17916779 - Targeted deletion of thioredoxin-interacting protein regulates cardiac dysfunction in r...
6507289 - Effects of nicardipine and nisoldipine on myocardial metabolism, coronary blood flow an...
10505429 - Load dependence of left ventricular contraction and relaxation. effects of caffeine.
10455469 - The influence of different antihypertensive drugs on left ventricular hypertrophy in a ...
17198909 - The g-231a polymorphism in the endothelin-a receptor gene is associated with lower aort...
16763189 - Cerebral vasodilatation to exogenous no is a measure of fitness for life at altitude.
4066589 - Effects of hemodynamic edema formation on peripheral vs. central airway mechanics.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Basic research in cardiology     Volume:  77     ISSN:  0300-8428     ISO Abbreviation:  Basic Res. Cardiol.     Publication Date:    1982 May-Jun
Date Detail:
Created Date:  1982-10-29     Completed Date:  1982-10-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0360342     Medline TA:  Basic Res Cardiol     Country:  GERMANY, WEST    
Other Details:
Languages:  eng     Pagination:  301-8     Citation Subset:  IM; X    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Coronary Disease / diagnosis,  pathology
Disease Models, Animal
Dogs
Female
Male
Molsidomine
Myocardial Infarction / diagnosis*,  pathology
Myocardium / pathology*
Organ Size / drug effects
Sydnones / pharmacology
Vasodilator Agents / pharmacology
Chemical
Reg. No./Substance:
0/Sydnones; 0/Vasodilator Agents; 25717-80-0/Molsidomine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of molsidomine on the coronary circulation in anesthetized dogs.
Next Document:  Isolation of two myosin light-chain kinases from bovine carotid artery and their regulation by phosp...